Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-Dual-IP
- Development stage
- Preclinical
- Lead developer
- Nanjing Nuoyuan Medical Equipment
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
NY-Dual-IP (often evaluated as the radiolabeled PET probe [68Ga]Ga-NY-Dual-IP) is a heterodimeric, dual-targeting molecular imaging agent designed to co-target integrin αvβ3 and poly(ADP-ribose) polymerase 1 (PARP1). Developed by Nuoyuan Medical in collaboration with Nanjing University, Nanjing Drum Tower Hospital, and Anhui Medical University, the probe utilizes a sequential "binding-anchoring" mechanism. The tumor-penetrating iRGD peptide moiety binds to integrin αvβ3 on tumor cells and activated tumor vasculature, facilitating tissue penetration and internalization via the CendR pathway. Once inside, the niraparib moiety binds to the NAD+ pocket of nuclear PARP1, anchoring the probe within the tumor cells. This dual-targeting approach is designed to overcome tumor heterogeneity and enhance diagnostic imaging performance in solid tumors, such as breast cancer.
- Other names
- 68Ga-NY-Dual-IP[68Ga]Ga-NY-Dual-IP
02
Targets
αVβ3 (Integrin αVβ3)NRP1 (Neuropilin-1)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on NY-Dual-IP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-Dual-IP.